title: Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial.
abstract: Despite the clinical benefit of statin therapy and the numerous strategies used to improve adherence, no strategy has used direct communication of genetic test results to the patient as an adherence and persistence motivator. We investigated in a real-world setting the effect of a process of providing KIF6 test results and risk information directly to 647 tested patients on 6-month statin adherence (proportion of days covered (PDC)) and persistence compared with concurrent non-tested matched controls. Adjusted 6-month statin PDC was significantly greater in tested patients: 0.77 (95% confidence interval (CI) 0.72-0.82) vs controls 0.68 (95% CI 0.63-0.73), P<0.0001. Significantly more tested patients were adherent (PDC⩾0.80) (63.4% (59.6-67.1%) vs 45.0% (41.1-48.8%), P<0.0001) and persisted on therapy (69.1% (65.4-72.5%) vs 53.3% (49.4-57.1%), P<0.0001). Similar results were observed in a secondary comparison with 779 unmatched patients who declined testing. The Additional KIF6 Risk Offers Better Adherence to Statins trial provides the first evidence that pharmacogenetic testing may modify patient adherence.
authors: 1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
authors: S L
authors: SL
authors: Charland
authors: 1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Avalere Health, LLC, Washington, DC, USA.
authors: B C
authors: BC
authors: Agatep
authors: Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA.
authors: V
authors: V
authors: Herrera
authors: 1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
authors: B
authors: B
authors: Schrader
authors: Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA.
authors: F W
authors: FW
authors: Frueh
authors: 1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Express Scripts, Franklin Lakes, NJ, USA.
authors: M
authors: M
authors: Ryvkin
authors: Ariosa Diagnostics, San Jose, CA, USA.
authors: J
authors: J
authors: Shabbeer
authors: Celera Corporation, Alameda, CA, USA.
authors: J J
authors: JJ
authors: Devlin
authors: Celera Corporation, Alameda, CA, USA.
authors: H R
authors: HR
authors: Superko
authors: Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA.
authors: E J
authors: EJ
authors: Stanek
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010597:Pharmacogenetics
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors